EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An orally available PfPKG inhibitor blocks Plasmodium’s infection of the liver

Hanna Dhiyebi, Aminata Mbaye, Anusha Thaniana, John Gilleran, Tyler Eck, Kutub Ashraf, Karl Kudyba, Howard Fan, Steve Seibold, Kevin P Battaile, John Siekierka, Evan Johnson und 6 weitere

PLOS Pathogens · 30.07.2026 · 22 (7) · e1014322

DOI: 10.1371/journal.ppat.1014322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 30.07.2026. Verfasst von Hanna Dhiyebi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Cyclic GMP-Dependent Protein Kinases, Liver. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, U.S. Department of Defense, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria remains a global health threat exacerbated by emerging resistance to antimalarial therapies and insecticides, climate-driven outbreaks, and limited chemoprotective options. Here, we report the characterization of RUPB-61 , the first orally bioavailable inhibitor of Plasmodium falciparum cGMP-dependent protein kinase (PfPKG). RUPB-61 prevents infection by P. falciparum and P. cynomolgi sporozoites, including the formation of hypnozoites by the latter. A single oral dose blocks liver infection by P. berghei sporozoites in vivo , demonstrating efficacy consistent with further development as a once-weekly prophylaxis based on pharmacokinetic modeling. The compound retains activity against field isolates resistant to chloroquine, mefloquine, cycloguanil, sulfadoxine and pyrimethamine, suggesting low likelihood of cross-resistance to existing antimalarials. Structural studies and free energy-based modeling guided-compound design prospectively validated the predictive accuracy of an in silico model of PfPKG interactions with this chemotype. While selectivity profiling identified off-target activity against human kinases, structural modeling provides a clear path for optimization. These results establish PfPKG inhibitors as promising candidates for chemoprevention and support further preclinical development of the RUPB-61 chemotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumCyclic GMP-Dependent Protein KinasesLiverMalariaProtein Kinase InhibitorsMalaria, FalciparumAnimalsMiceHumansAdministration, OralPlasmodium berghei

Substanzen

AntimalarialsCyclic GMP-Dependent Protein KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America.
  • Rutgers Molecular Design and Synthesis Core, Office for Research, Rutgers University, Piscataway, New Jersey, United States of America.
  • Department of Chemistry and Biochemistry and Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, New Jersey, United States of America.
  • Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Integrated Pathogen Therapeutics Department, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
  • Division of Infectious Disease, Department of Medicine and Center for Data Science, Rutgers New Jersey Medical SchoolNewark, New JerseyUnited States of America.

ORCID-Profile: Purnima Bhanot

Förderung

  • NIH HHS
  • U.S. Department of Defense
  • National Institute of Allergy and Infectious Diseases
  • Foundation for the National Institutes of Health

Zitieren

APA

Dhiyebi, H., Mbaye, A., Thaniana, A., Gilleran, J., Eck, T., Ashraf, K., Kudyba, K., Fan, H., Seibold, S., Battaile, K. P., Siekierka, J., Johnson, E., Roth, A., De Rocher, A., Lovell, S., Miller, E. B., Roberge, J. Y., & Bhanot, P. (2026). An orally available PfPKG inhibitor blocks Plasmodium’s infection of the liver. PLOS Pathogens, 22(7), e1014322. https://doi.org/10.1371/journal.ppat.1014322

Vancouver

Dhiyebi H, Mbaye A, Thaniana A, Gilleran J, Eck T, Ashraf K, et al. An orally available PfPKG inhibitor blocks Plasmodium’s infection of the liver. PLOS Pathogens. 2026;22(7):e1014322. doi:10.1371/journal.ppat.1014322

BibTeX
@article{Dhiyebi2026,
  author = {Dhiyebi, Hanna and Mbaye, Aminata and Thaniana, Anusha and Gilleran, John and Eck, Tyler and Ashraf, Kutub and Kudyba, Karl and Fan, Howard and Seibold, Steve and Battaile, Kevin P and Siekierka, John and Johnson, Evan and Roth, Alison and De Rocher, Amy and Lovell, Scott and Miller, Edward B and Roberge, Jacques Y and Bhanot, Purnima},
  title = {An orally available PfPKG inhibitor blocks Plasmodium’s infection of the liver},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {7},
  pages = {e1014322},
  doi = {10.1371/journal.ppat.1014322}
}
Kostenlos starten →